Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 17;83(6):833–839. doi: 10.1054/bjoc.2000.1363

Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line

T Tokunaga 1,2, T Tsuchida 1, H Kijima 1, K Okamoto 3, Y Oshika 1, N Sawa 3, Y Ohnishi 3, H Yamazaki 1, S Miura 2, Y Ueyama 1, M Nakamura 1
PMCID: PMC2363525  PMID: 10952790

Abstract

Mutation of c-K-ras oncogene is an important step in progression of colon cancer. We used a hammerhead ribozyme (KrasRz) against mutated K-ras gene transcripts (codon 12, GTT) to inactivate mutant K-ras function in the colon cancer cell line SW480, harbouring a mutant K-ras gene. The β-actin promoter-driven KrasRz sequence (pHβ/KrasRz) was introduced into these cells (SW480/KrasRz), and we evaluated its effects on growth of the colon cancer. The gene expression of angiogenesis-related molecules (vascular endothelial growth factor and thrombospondin) was also estimated in SW480/KrasRz. KrasRz specifically and efficiently cleaved the mutant K-ras mRNA but not wild-type mRNA in vitro. SW480/KrasRz showed decreased growth rate under tissue culture conditions (P< 0.01, Dunnett’s test). The xenotransplantability of SW480/KrasRz (XeSW480/KrasRz) was significantly decreased in nude mice (P< 0.05, Fisher’s exact test). Tumour volume of the xenografts XeSW480/KrasRz was significantly smaller than that of XeSW480/DisKrasRz (P< 0.01, Dunnett’s test). Gene expression of VEGF was suppressed in SW480/KrasRz, while TSP1 gene expression was enhanced. The SW480/KrasRz cells showed apoptosis-related features including nuclear condensation and DNA fragmentation. These results suggested that the hammerhead ribozyme-mediated inactivation of the mutated K-ras mRNA induced growth suppression, apoptosis and alteration of angiogenic factor expression. © 2000 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (330.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreyev H. J., Norman A. R., Cunningham D., Oates J. R., Clarke P. A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998 May 6;90(9):675–684. doi: 10.1093/jnci/90.9.675. [DOI] [PubMed] [Google Scholar]
  2. Bouffard D. Y., Ohkawa T., Kijima H., Irie A., Suzuki T., Curcio L. D., Holm P. S., Sassani A., Scanlon K. J. Oligonucleotide modulation of multidrug resistance. Eur J Cancer. 1996 Jun;32A(6):1010–1018. doi: 10.1016/0959-8049(96)00065-2. [DOI] [PubMed] [Google Scholar]
  3. Cech T. R., Zaug A. J., Grabowski P. J. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell. 1981 Dec;27(3 Pt 2):487–496. doi: 10.1016/0092-8674(81)90390-1. [DOI] [PubMed] [Google Scholar]
  4. Chi S., Kitanaka C., Noguchi K., Mochizuki T., Nagashima Y., Shirouzu M., Fujita H., Yoshida M., Chen W., Asai A. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene. 1999 Apr 1;18(13):2281–2290. doi: 10.1038/sj.onc.1202538. [DOI] [PubMed] [Google Scholar]
  5. Cho K. R., Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer. 1992 Sep 15;70(6 Suppl):1727–1731. doi: 10.1002/1097-0142(19920915)70:4+<1727::aid-cncr2820701613>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  6. Feng M., Cabrera G., Deshane J., Scanlon K. J., Curiel D. T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995 May 15;55(10):2024–2028. [PubMed] [Google Scholar]
  7. Fukushima Y., Oshika Y., Tsuchida T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol. 1998 Nov;13(5):967–970. doi: 10.3892/ijo.13.5.967. [DOI] [PubMed] [Google Scholar]
  8. Grugel S., Finkenzeller G., Weindel K., Barleon B., Marmé D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 1995 Oct 27;270(43):25915–25919. doi: 10.1074/jbc.270.43.25915. [DOI] [PubMed] [Google Scholar]
  9. Hsu S. C., Volpert O. V., Steck P. A., Mikkelsen T., Polverini P. J., Rao S., Chou P., Bouck N. P. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 1996 Dec 15;56(24):5684–5691. [PubMed] [Google Scholar]
  10. Jednak M. A., Nostrant T. T. Screening for colorectal cancer. Prim Care. 1998 Jun;25(2):293–308. doi: 10.1016/s0095-4543(05)70065-8. [DOI] [PubMed] [Google Scholar]
  11. Kieser A., Weich H. A., Brandner G., Marmé D., Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994 Mar;9(3):963–969. [PubMed] [Google Scholar]
  12. Kijima H., Ishida H., Ohkawa T., Kashani-Sabet M., Scanlon K. J. Therapeutic applications of ribozymes. Pharmacol Ther. 1995;68(2):247–267. doi: 10.1016/0163-7258(95)02008-x. [DOI] [PubMed] [Google Scholar]
  13. Kohl N. E., Mosser S. D., deSolms S. J., Giuliani E. A., Pompliano D. L., Graham S. L., Smith R. L., Scolnick E. M., Oliff A., Gibbs J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993 Jun 25;260(5116):1934–1937. doi: 10.1126/science.8316833. [DOI] [PubMed] [Google Scholar]
  14. Matsuguchi T., Kraft A. S. Regulation of myeloid cell growth by distinct effectors of Ras. Oncogene. 1998 Nov 26;17(21):2701–2709. doi: 10.1038/sj.onc.1202201. [DOI] [PubMed] [Google Scholar]
  15. Mukhopadhyay D., Tsiokas L., Sukhatme V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995 Dec 15;55(24):6161–6165. [PubMed] [Google Scholar]
  16. Ohta Y., Kijima H., Ohkawa T., Kashani-Sabet M., Scanlon K. J. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res. 1996 Mar 1;24(5):938–942. doi: 10.1093/nar/24.5.938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Okada F., Rak J. W., Croix B. S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R. S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609–3614. doi: 10.1073/pnas.95.7.3609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Oshika Y., Masuda K., Tokunaga T., Hatanaka H., Kamiya T., Abe Y., Ozeki Y., Kijima H., Yamazaki H., Tamaoki N. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res. 1998 Jul;4(7):1785–1788. [PubMed] [Google Scholar]
  19. Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Tamaoki N. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol. 1998 Mar;12(3):541–544. doi: 10.3892/ijo.12.3.541. [DOI] [PubMed] [Google Scholar]
  20. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995 Oct 15;55(20):4575–4580. [PubMed] [Google Scholar]
  21. Saraga E., Bautista D., Dorta G., Chaubert P., Martin P., Sordat B., Protiva P., Blum A., Bosman F., Benhattar J. Genetic heterogeneity in sporadic colorectal adenomas. J Pathol. 1997 Mar;181(3):281–286. doi: 10.1002/(SICI)1096-9896(199703)181:3<281::AID-PATH777>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  22. Scanlon K. J., Jiao L., Funato T., Wang W., Tone T., Rossi J. J., Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10591–10595. doi: 10.1073/pnas.88.23.10591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Scanlon K. J., Ohta Y., Ishida H., Kijima H., Ohkawa T., Kaminski A., Tsai J., Horng G., Kashani-Sabet M. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J. 1995 Oct;9(13):1288–1296. doi: 10.1096/fasebj.9.13.7557018. [DOI] [PubMed] [Google Scholar]
  24. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993 Apr 2;260(5104):85–88. doi: 10.1126/science.8465203. [DOI] [PubMed] [Google Scholar]
  25. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marmé D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 1996 May 15;56(10):2299–2301. [PubMed] [Google Scholar]
  26. Tokunaga T., Nakamura M., Oshika Y., Abe Y., Ozeki Y., Fukushima Y., Hatanaka H., Sadahiro S., Kijima H., Tsuchida T. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer. 1999 Jan;79(2):354–359. doi: 10.1038/sj.bjc.6690056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tokunaga T., Nakamura M., Oshika Y., Tsuchida T., Kazuno M., Fukushima Y., Kawai K., Abe Y., Kijima H., Yamazaki H. Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch. 1998 Nov;433(5):415–418. doi: 10.1007/s004280050268. [DOI] [PubMed] [Google Scholar]
  28. Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Ueyama Y., Tamaoki N. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998 Mar;77(6):998–1002. doi: 10.1038/bjc.1998.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tomisawa M., Tokunaga T., Oshika Y., Tsuchida T., Fukushima Y., Sato H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999 Jan;35(1):133–137. doi: 10.1016/s0959-8049(98)00278-0. [DOI] [PubMed] [Google Scholar]
  30. Tsuchida T., Kijima H., Oshika Y., Tokunaga T., Abe Y., Yamazaki H., Tamaoki N., Ueyama Y., Scanlon K. J., Nakamura M. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem Biophys Res Commun. 1998 Dec 18;253(2):368–373. doi: 10.1006/bbrc.1998.9789. [DOI] [PubMed] [Google Scholar]
  31. Tsuchida T., Kijima H., Tokunaga T., Oshika Y., Hatanaka H., Fukushima Y., Abe Y., Kawai K., Yoshida Y., Miura S. Expression of the thrombospondin 1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int J Oncol. 1999 Jan;14(1):47–51. [PubMed] [Google Scholar]
  32. Ward R. L., Todd A. V., Santiago F., O'Connor T., Hawkins N. J. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997 Mar 15;79(6):1106–1113. [PubMed] [Google Scholar]
  33. Yamazaki H., Kijima H., Ohnishi Y., Abe Y., Oshika Y., Tsuchida T., Tokunaga T., Tsugu A., Ueyama Y., Tamaoki N. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst. 1998 Apr 15;90(8):581–587. doi: 10.1093/jnci/90.8.581. [DOI] [PubMed] [Google Scholar]
  34. Zabrenetzky V., Harris C. C., Steeg P. S., Roberts D. D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer. 1994 Oct 15;59(2):191–195. doi: 10.1002/ijc.2910590209. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES